What Is Immunotherapy? How It Helps the Body Fight Cancer

For many people, cancer treatment brings to mind surgery, chemotherapy, or radiation. Immunotherapy can feel less familiar, even though it has become an important part of modern cancer care. Instead of attacking cancer directly in the same way some traditional treatments do, immunotherapy helps the immune system recognize, target, or control cancer cells more effectively.

The idea sounds simple, but the science behind it is remarkable. The immune system already protects the body from infections and abnormal cells every day. Cancer, however, can sometimes hide from immune defenses or send signals that make immune cells slow down. Immunotherapy is designed to help remove some of those barriers, boost immune activity, or guide the body’s defenses toward cancer.

This treatment is not used for every person or every cancer type. It may be recommended for certain cases of melanoma, lung cancer, kidney cancer, bladder cancer, lymphoma, leukemia, and other cancers, depending on the diagnosis, stage, biomarkers, and overall health. The American Cancer Society explains that immunotherapy works with the body’s immune system to kill cancer cells or limit their growth.

Its reach has grown fast. A 2024 estimate reported that eligibility for immune checkpoint inhibitors rose from 1.54% of cancer patients in 2011 to 55.47% in 2023, showing how quickly this field has expanded. Still, eligibility does not always mean response, and results can vary from one person to another.

In this article, I’ll walk through what immunotherapy is, how it helps the body fight cancer, who may receive it, and what side effects or limitations patients should understand. Keep reading to explore the basics before your next conversation with a healthcare provider.

What is Immunotherapy?

Immunotherapy for cancer is a type of biological therapy that utilizes substances made from living organisms to help the body’s own immune system fight cancer more effectively. Its core principle is to overcome the mechanisms that cancer cells use to evade immune detection, thereby enabling the body’s natural defenses to recognize and eliminate malignant cells.

Immunotherapy vs. Chemotherapy

Immunotherapy fundamentally differs from chemotherapy in its mechanism of action: immunotherapy empowers the patient’s immune system to selectively kill cancer cells, whereas chemotherapy uses powerful cytotoxic drugs to directly kill rapidly dividing cells throughout the body. This distinction in approach leads to significant differences in how they work, their side effects, and their potential for long-term efficacy.

Chemotherapy is a systemic treatment that targets any cell that divides quickly, which includes not only cancer cells but also healthy cells in the bone marrow, hair follicles, and digestive tract. This lack of specificity is why chemotherapy is associated with common side effects like hair loss, nausea, fatigue, and an increased risk of infection. It acts as a broad-spectrum poison against cellular proliferation.

In contrast, immunotherapy works indirectly by modulating the immune system. For example, immune checkpoint inhibitors, a common type of immunotherapy, don’t kill cancer cells themselves. Instead, they block the “off switches” (checkpoints) that cancer cells exploit to hide from immune cells called T-cells.

By releasing these brakes, immunotherapy allows the T-cells to recognize the cancer as a foreign invader and mount a targeted attack. This targeted action often leads to a different profile of side effects. Instead of widespread cytotoxicity, side effects from immunotherapy are typically immune-related, occurring when the newly activated immune system mistakenly attacks healthy tissues, which can cause inflammation in organs like the colon (colitis), lungs (pneumonitis), or skin (rash).

Furthermore, because immunotherapy can create “memory” T-cells, its effects can be durable, with the potential for long-lasting remissions even after treatment has stopped, a feature less common with chemotherapy.

Is Immunotherapy a New form of Cancer Treatment?

The answer is both yes and no; the concept of using the immune system to fight cancer is over a century old, but the highly effective and specific immunotherapies used today are the result of recent scientific breakthroughs. The foundational idea dates back to the late 19th century with Dr. William B. Coley, a surgeon who observed that some cancer patients who developed bacterial infections experienced spontaneous tumor regression.

He theorized that the infection stimulated an immune response that also attacked the cancer. He developed Coley’s toxins, a mixture of heat-killed bacteria, to intentionally induce this immune stimulation, achieving some success. However, his work was largely overshadowed by the advent of radiation and chemotherapy, which offered more predictable, albeit toxic, results.

The modern era of immunotherapy began with a deeper understanding of molecular immunology, particularly the discovery of immune checkpoints. In the 1990s, scientists James P. Allison and Tasuku Honjo made groundbreaking discoveries about CTLA-4 and PD-1, respectively, proteins that act as brakes on T-cells. They hypothesized that blocking these brakes could unleash the immune system to attack cancer.

This research culminated in the development of the first immune checkpoint inhibitors in the 2010s, which led to unprecedented success in treating advanced cancers like melanoma and lung cancer. Their work earned them the 2018 Nobel Prize in Physiology or Medicine. So, while the principle is old, the precise, molecular-level interventions that define modern immunotherapy, such as checkpoint inhibitors and CAR T-cell therapy, are truly new and have only become a pillar of cancer care in the last decade.

How Does the Mechanism of Immunotherapy Work Against Cancer?

The mechanism of immunotherapy works by disrupting the strategies cancer cells use to hide from the immune system, thereby enabling immune cells, particularly T-cells, to recognize and launch a sustained attack against tumors. It essentially re-educates and re-energizes the body’s natural defenses to overcome cancer’s evasive tactics.

How Does The Immune System Normally Recognize and Fight Disease?

The immune system normally recognizes and fights disease by distinguishing between self (the body’s own healthy cells) and non-self (foreign invaders like bacteria, viruses, or abnormal cells like cancer). This sophisticated surveillance system relies on specialized white blood cells, with T-cells and antigen-presenting cells (APCs) playing a central role.

Every cell in the body displays protein fragments, called antigens, on its surface using a molecule called the major histocompatibility complex (MHC). For healthy cells, these are self-antigens, which the immune system is trained to ignore. However, when a cell is infected by a virus or becomes cancerous, it starts to produce abnormal proteins and displays foreign or mutated antigens on its surface.

This is where the recognition process begins. APCs, such as dendritic cells, act as sentinels, patrolling the body for these abnormal antigens. When an APC encounters a cancer cell, it engulfs it and presents the cancerous antigens on its own surface.

The APC then travels to a lymph node, where it presents this antigen to a specific type of T-cell. This interaction activates the T-cell, transforming it into a killer T-cell (cytotoxic T-lymphocyte). These activated T-cells then multiply and circulate throughout the body, hunting for any cell that displays the same cancerous antigen.

Upon finding a match, the killer T-cell binds to the cancer cell and releases cytotoxic chemicals, such as perforin and granzymes, which punch holes in the cancer cell’s membrane and trigger its self-destruction (apoptosis). This highly specific and powerful process is the body’s natural defense against the development of cancer.

Why Does Cancer Often Go Undetected By The Immune System?

Cancer often goes undetected by the immune system because it evolves sophisticated mechanisms to evade recognition and destruction, primarily by exploiting natural checkpoints that regulate immune responses. The immune system has built-in brakes, known as immune checkpoints, to prevent it from becoming overactive and attacking healthy tissues, which could lead to autoimmune diseases.

These checkpoints are controlled by proteins on the surface of immune cells and other cells in the body. One of the most critical checkpoint pathways involves the protein PD-1 (programmed cell death protein 1) on the surface of T-cells and its partner protein, PD-L1 (programmed death-ligand 1), which can be expressed on other cells, including some cancer cells.

When a T-cell’s PD-1 receptor binds to the PD-L1 ligand on another cell, it sends an inhibitory off signal to the T-cell, telling it to stand down and leave the other cell alone. This is a normal process to maintain self-tolerance. However, many types of cancer have co-opted this safety mechanism for their own survival. They can produce high levels of PD-L1 on their surface, effectively putting up a do not attack sign.

When an activated T-cell approaches a cancer cell expressing PD-L1, the interaction between PD-1 and PD-L1 deactivates the T-cell, preventing it from launching its attack. The cancer cell essentially uses this molecular disguise to masquerade as healthy tissue and hide in plain sight.

In addition to this primary mechanism, cancer cells can also reduce the number of tumor antigens on their surface, making them less visible to T-cells, or they can secrete substances that suppress the local immune environment, further hindering the immune response. Immunotherapy is designed to counteract these very evasion strategies.

Main Types of Immunotherapy Used in Cancer Treatment

There are four main types of immunotherapy used in cancer treatment: immune checkpoint inhibitors, CAR T-cell therapy, monoclonal antibodies, and cancer vaccines, each employing a distinct strategy to mobilize the immune system against cancer.

These approaches can be used alone or in combination with other treatments like chemotherapy to enhance their effectiveness. Next, we will examine the mechanisms of some of the most prominent and innovative types of immunotherapy in modern oncology.

Immune Checkpoint Inhibitors

Immune checkpoint inhibitors are a class of immunotherapy drugs that work by blocking the specific proteins that function as “brakes” or “off switches” on the immune system, thereby unleashing a more powerful and sustained anti-cancer response. These drugs do not target cancer cells directly; instead, they target the regulatory pathways within the immune system itself.

The most well-known checkpoints are CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), PD-1 (programmed cell death protein 1), and its ligand, PD-L1. Under normal conditions, these checkpoints are crucial for preventing autoimmunity by stopping immune cells, particularly T-cells, from attacking the body’s healthy tissues. However, many cancer cells have learned to exploit these pathways to evade destruction.

For example, a tumor cell can express high levels of PD-L1 on its surface. When a T-cell, which has the PD-1 receptor, comes into contact with this tumor cell, the binding of PD-1 to PD-L1 sends a powerful inhibitory signal that deactivates the T-cell. The T-cell, despite having recognized the cancer, is effectively shut down.

Checkpoint inhibitor drugs, which are a type of monoclonal antibody, are designed to physically block this interaction. An anti-PD-1 drug (like nivolumab or pembrolizumab) will bind to the PD-1 receptor on the T-cell, preventing the tumor’s PD-L1 from engaging it. Similarly, an anti-PD-L1 drug (like atezolizumab or durvalumab) will bind to the PD-L1 ligand on the tumor cell.

In either case, the “off” signal is interrupted. This “releases the brakes” on the T-cell, allowing it to remain active and proceed with its mission of killing the cancer cell. This approach has revolutionized the treatment of many advanced cancers, including melanoma, lung cancer, and kidney cancer.

CAR T-cell Therapy

CAR T-cell therapy is a highly personalized and potent form of immunotherapy, often called a “living drug,” where a patient’s own T-cells are extracted, genetically engineered in a laboratory to better recognize and fight cancer, and then reinfused back into the patient. The process begins with leukapheresis, a procedure similar to donating blood, where T-cells are separated from the patient’s bloodstream.

These collected T-cells are then sent to a specialized manufacturing facility. In the lab, scientists use a disabled virus (typically a lentivirus or retrovirus) to deliver a new gene into the T-cells’ DNA. This gene instructs the T-cells to produce special synthetic receptors on their surface called Chimeric Antigen Receptors, or CARs.

These CARs are specifically designed to recognize and bind to a particular antigen present on the surface of the patient’s cancer cells. For example, in many B-cell leukemias and lymphomas, the target antigen is CD19. Once the T-cells have been successfully engineered to express these CARs, they are multiplied into the hundreds of millions.

Before the newly engineered CAR T-cells are infused back into the patient, the patient often receives a short course of low-dose chemotherapy. This is not to treat the cancer but to temporarily deplete some of the existing immune cells to make space for the incoming CAR T-cells to expand and thrive. After infusion, these supercharged CAR T-cells circulate throughout the body, acting as a highly targeted search-and-destroy team.

When they encounter a cancer cell displaying the target antigen, the CAR binds to it, triggering a powerful activation of the T-cell, which then multiplies and kills the cancer cell. This approach has shown remarkable success in treating certain types of advanced blood cancers that have stopped responding to other treatments.

Monoclonal Antibodies

Monoclonal antibodies are laboratory-produced molecules that are engineered to serve as substitute antibodies, designed to attach to specific target antigens on the surface of cancer cells with high precision.

Unlike the polyclonal antibodies our bodies naturally produce in response to an infection (which can recognize multiple antigens), monoclonal antibodies are identical clones derived from a single parent cell, meaning they all recognize and bind to the exact same epitope on a single antigen. This specificity makes them a powerful tool in cancer therapy.

Once administered to a patient, they circulate through the body until they find and attach to their designated target on cancer cells. Their mechanism of action can vary depending on their design.

Some monoclonal antibodies work by marking cancer cells. By binding to the cancer cell’s surface, they act as a flag, making the cancer cell more visible and recognizable to the immune system. This process, known as antibody-dependent cell-mediated cytotoxicity (ADCC), encourages other immune cells, like natural killer (NK) cells, to identify and destroy the marked cancer cell.

Other monoclonal antibodies, often called targeted therapy, are designed to block critical growth signals. For example, if a cancer cell relies on a specific growth factor receptor to proliferate, a monoclonal antibody can be designed to bind to that receptor, effectively blocking the growth signal and preventing the cancer cell from dividing.

A third type, known as antibody-drug conjugates (ADCs), function as guided missiles. In this approach, a potent chemotherapy drug is attached to the monoclonal antibody. The antibody seeks out and binds to the cancer cell, and only then is the chemotherapy toxin released directly into the cancer cell, minimizing damage to surrounding healthy tissues. Examples include trastuzumab (Herceptin) for breast cancer and rituximab (Rituxan) for certain lymphomas.

Types of Cancer can be Treated with Immunotherapy

Immunotherapy can be used to treat a broad and growing range of cancers, including but not limited to melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancers, Hodgkin lymphoma, and certain types of leukemia. Its effectiveness is not strictly defined by the organ of origin but rather by the biological characteristics of the tumor, such as its expression of immune checkpoint proteins or its mutational burden. A

s research advances, the list of cancers responsive to various forms of immunotherapy continues to expand, making it a versatile and integral part of modern cancer care.

Skin and Lung Cancers

Immunotherapy, particularly immune checkpoint inhibitors, has proven to be exceptionally effective for certain types of skin and lung cancers, which were among the first solid tumors to show dramatic and durable responses to this class of treatment. Melanoma, an aggressive form of skin cancer, and non-small cell lung cancer (NSCLC) were landmark diseases in the development of immunotherapy.

The reason for this high efficacy is believed to be linked to their high tumor mutational burden (TMB). Both melanoma (often caused by UV radiation from sun exposure) and NSCLC (frequently caused by carcinogens in tobacco smoke) tend to accumulate a large number of genetic mutations.

Each mutation has the potential to create a new, abnormal protein, which can then be presented on the cancer cell’s surface as a neoantigen. These neoantigens look foreign to the immune system, making the cancer cells more visible and immunogenic – that is, more likely to provoke an immune response. A tumor with a high number of neoantigens provides many more potential targets for T-cells to recognize and attack.

When checkpoint inhibitors are administered, they release the brakes on these T-cells, allowing them to effectively target the highly mutated cancer cells. For patients with advanced melanoma, immunotherapy has transformed the prognosis, leading to long-term survival rates that were unimaginable just over a decade ago.

Similarly, for a significant subset of patients with advanced NSCLC, immunotherapy has become a first-line standard of care, often providing more durable responses and a better quality of life compared to traditional chemotherapy.

Blood Cancers like Leukemia and Lymphoma

Immunotherapy has emerged as a revolutionary treatment for several types of blood cancers, particularly certain forms of leukemia and lymphoma, with CAR T-cell therapy being one of the most prominent examples of its success.

While checkpoint inhibitors are approved for some blood cancers, like Hodgkin lymphoma, it is the advent of CAR T-cell therapy that has truly transformed the landscape for patients with relapsed or refractory hematologic malignancies. This “living drug” approach is specifically designed to target antigens that are highly expressed on the surface of cancerous blood cells.

For example, many B-cell cancers, such as B-cell acute lymphoblastic leukemia (ALL) and several types of non-Hodgkin lymphoma (like diffuse large B-cell lymphoma), express a protein called CD19 on their cell surfaces. CAR T-cell therapies like tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) are engineered to seek out and bind to this CD19 target.

For patients, often children and young adults with ALL or adults with aggressive lymphomas who have exhausted all other treatment options, CAR T-cell therapy has produced unprecedented rates of complete remission. The therapy involves extracting a patient’s T-cells, genetically modifying them to recognize the CD19 antigen, and reinfusing them to hunt down and eliminate the cancerous B-cells.

In addition to CAR T-cell therapy, other immunotherapies like monoclonal antibodies (e.g., rituximab, which targets the CD20 antigen on B-cells) have long been a standard of care for lymphomas, further demonstrating the vital role of immunotherapy in treating blood cancers.

What Else Should Patients Know About Immunotherapy?

Beyond its basic mechanisms, patients should understand immunotherapy’s potential side effects, eligibility criteria, use in combination with other treatments, and the exciting future of this therapeutic approach. Furthermore, grasping these practical aspects provides a more complete picture of what to expect during and after treatment, empowering patients to have more informed discussions with their healthcare team.

Common Side Effects of Immunotherapy

The side effects of immunotherapy are distinct from those of chemotherapy because they stem from an overactive immune system rather than from direct damage to rapidly dividing cells. These are known as immune-related adverse events (irAEs) and can affect any organ system. Instead of hair loss or nausea being primary concerns, patients may experience conditions that resemble autoimmune disorders.

Common side effects often involve inflammation in various parts of the body. For example, skin reactions like rashes, itching, and vitiligo are frequent. Inflammation of the colon, called colitis, can lead to diarrhea and abdominal pain.

Other common irAEs include inflammation of the lungs (pneumonitis), liver (hepatitis), and endocrine glands, which can cause fatigue by affecting the thyroid (thyroiditis) or pituitary gland (hypophysitis). While many of these side effects are mild to moderate and can be managed with medications like corticosteroids to suppress the immune response, some can be severe or even life-threatening if not addressed promptly.

Who is a Good Candidate for Immunotherapy Treatment?

Determining who is a good candidate for immunotherapy is a complex process that depends on several interconnected factors, moving beyond just the type and stage of cancer. A crucial element is the use of biomarker testing, which analyzes specific characteristics of the tumor cells or the tumor microenvironment.

One of the most common biomarkers is the expression level of a protein called PD-L1 (Programmed death-ligand 1) on cancer cells; higher levels often predict a better response to checkpoint inhibitors.

Other important biomarkers include tumor mutational burden (TMB), which measures the number of mutations within a tumor’s DNA, and microsatellite instability (MSI), an indicator of a faulty DNA repair system. Tumors with high TMB or high MSI are often more responsive to immunotherapy because they produce more abnormal proteins, or neoantigens, that the immune system can recognize and target.

Beyond biomarkers, several other patient-specific factors are critical in determining suitability for this treatment. A patient’s overall health and performance status are significant, as they must be well enough to tolerate potential side effects.

The specific type and stage of cancer are paramount, as immunotherapy is approved for certain cancers and not others, and its effectiveness can vary by disease progression.

Also, a patient’s history of autoimmune diseases, such as lupus or rheumatoid arthritis, is a major consideration, as immunotherapy could potentially exacerbate these pre-existing conditions by further stimulating the immune system.

Can Immunotherapy be Combined With Other Cancer Treatments?

Immunotherapy is frequently and effectively combined with other standard cancer treatments to improve patient outcomes. The rationale behind these combination therapies is to create a synergistic effect, where the combined impact is greater than the sum of the individual treatments. By attacking the cancer from multiple angles simultaneously, clinicians can overcome treatment resistance and enhance the body’s ability to eradicate malignant cells.

For instance, combining immunotherapy with chemotherapy is a common strategy. Chemotherapy can kill cancer cells in a way that releases tumor-specific antigens, effectively unmasking the tumor and making it more visible to the newly activated immune system.

Similarly, radiation therapy can have a similar antigen-releasing effect and may also help recruit immune cells to the tumor site, turning a cold tumor (with few immune cells) into a hot one that is more responsive to immunotherapy. This phenomenon is known as the abscopal effect, where irradiating one tumor can lead to the shrinkage of other tumors elsewhere in the body through a systemic immune response.

This multi-pronged approach has led to new standards of care for various cancers, including certain types of lung cancer, breast cancer, and head and neck cancers. Specifically, chemo-immunotherapy leverages the cell-killing power of chemotherapy with the sustained, targeted attack of the immune system. Radiation-immunotherapy can amplify the immune response not just at the site of radiation but throughout the body.

For cancers with specific genetic mutations, combining a targeted drug that blocks the mutation’s pathway with an immune checkpoint inhibitor can deliver a powerful one-two punch against the disease.

The Future of Immunotherapy Research

The future of immunotherapy research is focused on personalization, expanding its effectiveness, and discovering new ways to engage the immune system. One of the most promising frontiers is the development of personalized cancer vaccines. These are not preventative vaccines but therapeutic ones, created by analyzing a patient’s specific tumor mutations to identify unique neoantigens.

A vaccine is then custom-built to teach the patient’s immune system to recognize and attack only cells containing those specific markers, offering a highly targeted and potentially less toxic treatment. Another major area of research involves identifying and targeting new immune checkpoints beyond the well-known PD-1/PD-L1 and CTLA-4 pathways. Molecules like LAG-3, TIM-3, and TIGIT are being actively investigated as the next generation of targets to overcome resistance to current therapies.

Researchers are also exploring ways to manipulate the tumor microenvironment—the complex ecosystem of blood vessels, immune cells, and structural molecules surrounding a tumor—to make it more receptive to an immune attack. This includes developing therapies that can convert suppressive immune cells into cancer-fighting ones.

This forward-looking research aims to make immunotherapy a viable option for a broader range of patients and cancer types. Scientists are working to enhance CAR-T cell therapy to make it effective against solid tumors, not just blood cancers, by engineering the cells to better survive and penetrate dense tumor tissues.

Plus, a significant focus is on understanding why some patients do not respond to immunotherapy and developing strategies to reverse this resistance, often through novel combination therapies. There is growing evidence that the gut microbiome influences a patient’s response to immunotherapy, opening up the possibility of modifying a patient’s gut bacteria to improve treatment outcomes.

FAQs

1. What is life expectancy with immunotherapy?

Life expectancy with immunotherapy depends on the cancer type, stage, tumor biology, treatment response, overall health, and whether other therapies are used. Some people have a strong and lasting response, especially when their cancer has biomarkers that make immunotherapy more likely to work. Others may see little benefit.

It is not possible to give one survival number for all patients because immunotherapy is used across many cancers, from melanoma and lung cancer to bladder cancer, kidney cancer, lymphoma, and others. A person’s oncologist can give the most realistic outlook based on scans, lab results, treatment goals, and response over time.

2. At what stage of cancer is immunotherapy used?

Immunotherapy may be used in different stages of cancer, not only advanced disease. In some cases, it is used for metastatic or recurrent cancer. In others, it may be given before surgery, after surgery, or along with chemotherapy or radiation to lower the chance of cancer returning.

The decision depends on the cancer type, stage, genetic markers, immune markers, and approved treatment options. Cancer Research UK explains that immunotherapy helps the immune system recognize and attack cancer cells, but not every cancer responds in the same way.

3. What is the downside of immunotherapy?

The main downside is that immunotherapy does not work for everyone, and side effects can sometimes be serious. Because it activates or changes the immune system, it may cause the body to attack healthy tissue.

Side effects can include fatigue, rash, diarrhea, fever, nausea, breathing problems, hormone changes, or inflammation in organs such as the lungs, liver, colon, thyroid, or kidneys. The National Cancer Institute notes that side effects may include fever, chills, weakness, dizziness, nausea, fatigue, headache, breathing trouble, blood pressure changes, diarrhea, infection, and organ inflammation.

4. Is immunotherapy end of life care?

Immunotherapy is not the same as end-of-life care. It is an active cancer treatment used to control, shrink, or slow cancer in selected patients. Some people receive it when cancer is advanced, but that does not mean the treatment is only palliative or only used near the end of life.

In certain cancers, immunotherapy can be part of a long-term treatment plan, and in some cases, it may help produce durable remission. However, if cancer no longer responds or the side effects become too severe, doctors may shift the focus toward comfort care.

5. How long do patients stay on immunotherapy?

Some patients stay on immunotherapy for a few months, while others continue for one or two years, or sometimes longer in selected cases. The schedule depends on the drug, cancer type, response, side effects, and treatment goal. Treatment may stop if scans show cancer progression, if side effects become unsafe, or if the patient completes a planned course.

Some people also stop after a deep response and remain under close monitoring. Follow-up visits are still important because immune-related side effects can sometimes appear even after treatment ends. The American Cancer Society notes that immune-related effects may happen during treatment or after stopping immunotherapy.

6. Which cancers are most successfully treated with immunotherapy?

Immunotherapy has shown meaningful success in several cancers, especially melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancers, certain lymphomas, some leukemias, and cancers with specific biomarkers such as MSI-high or mismatch repair deficiency. It has changed treatment expectations for some patients, but success is not guaranteed.

The Cancer Research Institute reports that more than 40 immunotherapy drugs have been approved to treat over 30 cancer types, showing how widely this field has grown.

Conclusion

Immunotherapy has changed the way many cancers are treated, offering another path beyond surgery, chemotherapy, and radiation. It works by helping the immune system find and fight cancer cells, but it is not a universal answer. Some patients respond well and may experience long-lasting control. Others may not respond, or they may develop side effects that need close medical attention.

The most important point is personalization. Cancer type, stage, biomarkers, prior treatments, and overall health all shape whether immunotherapy is a good option. That is why patients should talk with their oncology team about expected benefits, possible risks, treatment length, warning signs, and how progress will be measured.

For anyone newly learning about immunotherapy, the topic may feel complex at first. Start with the basics, ask clear questions, and keep every treatment decision grounded in your own diagnosis. The more you understand how immunotherapy works, the easier it becomes to take part in conversations about care, hope, and realistic next steps.

References

• American Cancer Society – Immunotherapy
• National Institutes of Health – Immunotherapy to Treat Cancer
• Cancer Research Institute – Immunotherapy for Your Cancer Type
• Cancer Research UK – What is immunotherapy?
• Fred Hutchinson Cancer Center – Immunotherapy for Cancer
• Dana-Farber Cancer Institute – Immunotherapy
• UCSF Health – Immunotherapy
• Penn Medicine – Immunotherapy
• Cancer Council – Immunotherapy
• The University of Texas MD Anderson Cancer Center – Immunotherapy
• American Lung Association – Lung Cancer Immunotherapy